<p>Enliven Therapeutics（纳斯达克股票代码：ELVN - 获取免费报告）于周二公布了其季度财报。公司报告称，该季度每股收益（EPS）为（$0.41），超过了预期的（$0.58）$0.17，据 Zacks 报道。</p>
<p>获取 <strong>Enliven Therapeutics</strong> 的警报：</p>
<h2>Enliven Therapeutics 股价上涨 6.0%</h2>
<p>纳斯达克 ELVN 周四上涨$1.31，达到$23.11。该公司的股票交易量为 105,264 股，相比平均交易量 266,162 股。该公司市值为 10.9 亿美元，市盈率为-11.74，贝塔系数为 1.10。公司的 50 天简单移动平均线为$22.77，200 天简单移动平均线为$20.02。Enliven Therapeutics 的 52 周最低价为$9.80，52 周最高价为$27.67。</p>
<h2>华尔街分析师预测增长</h2>
<p>最近一些券商对 ELVN 发表了看法。Robert W. Baird 于 6 月 11 日星期二开始对 Enliven Therapeutics 的股票进行覆盖。他们给出了 “跑赢市场” 评级，并在股票上设定了 32.00 美元的目标价。Baird R W 在 6 月 11 日星期二的报告中将 Enliven Therapeutics 的评级提升至 “强烈买入”。</p>
<p>获取我们对 Enliven Therapeutics 的最新研究报告</p>
<h2>内部人员的买卖行为</h2>
<p>另外，首席运营官 Anish Patel 于 7 月 12 日星期五出售了公司股票的 17,475 股。股票的平均售价为 25.07 美元，总价值为 438,098.25 美元。交易完成后，首席运营官在公司拥有 376,552 股股票，价值约 9,440,158.64 美元。该交易已在提交给证券交易委员会（SEC）的文件中披露，可在 SEC 网站上查看。此外，首席运营官 Anish Patel 于 7 月 12 日星期五以 25.07 美元的平均价格出售了 17,475 股 Enliven Therapeutics 股票。交易完成后，首席运营官现在直接持有公司 376,552 股股票，价值 9,440,158.64 美元。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站查看。此外，内部人员 Joseph P. Lyssikatos 于 7 月 31 日星期三出售了 3,099 股 Enliven Therapeutics 股票。股票以 27.56 美元的平均价格出售，总价值为 85,408.44 美元。交易后，该内部人员现在持有公司 1,089,936 股股票，价值约 30,038,636.16 美元。上一季度内部人员出售了价值 3057633 美元的公司股票 123,668 股。公司股份的 29.20% 归内部人员所有。</p>
<h2>关于 Enliven Therapeutics（获取免费报告）</h2>
<p>Enliven Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于发现和开发小分子抑制剂，以帮助癌症患者。该公司的主要产品候选包括正在评估中的 ELVN-001，用于慢性髓细胞白血病成人的 I 期临床试验；以及用于具有 HER2 改变的实体肿瘤成人的 I 期临床试验的 ELVN-002。</p>
<h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票比 Enliven Therapeutics 更好</li>
<li>什么是 SEC 备案？</li>
<li>迈克尔·伯里的阿里巴巴赌注及其对整个市场的影响</li>
<li>ETF 是否支付股息？你需要了解的</li>
<li>杰夫·布朗的 Exegesis AI 股票推荐</li>
<li>投资高市盈率成长股</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔哈撒韦买入了 Ulta 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxWTg"/></p>
<p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 伊隆（Elon）追逐人工智能财富（来自 InvestorPlace）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc3"/></p>
<h2>您现在是否应该投资 1000 美元购买 Enliven Therapeutics？</h2>
<p>在考虑投资 Enliven Therapeutics 之前，您需要听到这个。</p>
<p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Enliven Therapeutics 不在名单上。</p>
<p>尽管 Enliven Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ELVN

<p>Enliven Therapeutics (NASDAQ:ELVN) 发布了季度财报，实现了每股收益（{{.Question}}.41），超过了预期的（{{.Question}}.58）{{.Question}}.17。随后，股价上涨了 6.0%。该公司的市值为 90 亿美元，市盈率为-11.74。内部交易包括首席运营官 Anish Patel 出售股票，分析师最近将该公司的评级升级为 “强烈买入”。Enliven Therapeutics 专注于开发用于癌症治疗的小分子抑制剂，目前有两个主导产品候选正在临床试验中</p>

<p>Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17, Zacks reports.</p>
<div class="lb-trans"><p>Enliven Therapeutics（纳斯达克股票代码：ELVN - 获取免费报告）于周二公布了其季度财报。公司报告称，该季度每股收益（EPS）为（$0.41），超过了预期的（$0.58）$0.17，据 Zacks 报道。</p>
</div><p>Get <strong>Enliven Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Enliven Therapeutics</strong> 的警报：</p>
</div><h2>Enliven Therapeutics Trading Up 6.0 %</h2>
<div class="lb-trans"><h2>Enliven Therapeutics 股价上涨 6.0%</h2>
</div><p>NASDAQ ELVN traded up $1.31 on Thursday, hitting $23.11. The company's stock had a trading volume of 105,264 shares, compared to its average volume of 266,162. The firm has a market cap of $1.09 billion, a P/E ratio of -11.74 and a beta of 1.10. The company's 50-day simple moving average is $22.77 and its 200 day simple moving average is $20.02. Enliven Therapeutics has a 52-week low of $9.80 and a 52-week high of $27.67.</p>
<div class="lb-trans"><p>纳斯达克 ELVN 周四上涨$1.31，达到$23.11。该公司的股票交易量为 105,264 股，相比平均交易量 266,162 股。该公司市值为 10.9 亿美元，市盈率为-11.74，贝塔系数为 1.10。公司的 50 天简单移动平均线为$22.77，200 天简单移动平均线为$20.02。Enliven Therapeutics 的 52 周最低价为$9.80，52 周最高价为$27.67。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages recently weighed in on ELVN. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an &#34;outperform&#34; rating and a $32.00 target price on the stock. Baird R W upgraded Enliven Therapeutics to a &#34;strong-buy&#34; rating in a report on Tuesday, June 11th.</p>
<div class="lb-trans"><p>最近一些券商对 ELVN 发表了看法。Robert W. Baird 于 6 月 11 日星期二开始对 Enliven Therapeutics 的股票进行覆盖。他们给出了 “跑赢市场” 评级，并在股票上设定了 32.00 美元的目标价。Baird R W 在 6 月 11 日星期二的报告中将 Enliven Therapeutics 的评级提升至 “强烈买入”。</p>
</div><p><strong>Get Our Latest Research Report on Enliven Therapeutics</strong></p>
<div class="lb-trans"><p>获取我们对 Enliven Therapeutics 的最新研究报告</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员的买卖行为</h2>
</div><p>In other news, COO Anish Patel sold 17,475 shares of the firm's stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $25.07, for a total value of $438,098.25. Following the completion of the transaction, the chief operating officer now owns 376,552 shares in the company, valued at approximately $9,440,158.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, COO Anish Patel sold 17,475 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $25.07, for a total transaction of $438,098.25. Following the completion of the transaction, the chief operating officer now directly owns 376,552 shares in the company, valued at $9,440,158.64. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 3,099 shares of Enliven Therapeutics stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $27.56, for a total value of $85,408.44. Following the transaction, the insider now owns 1,089,936 shares of the company's stock, valued at approximately $30,038,636.16. The disclosure for this sale can be found here. Insiders sold 123,668 shares of company stock valued at $3,057,633 over the last quarter. 29.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>另外，首席运营官 Anish Patel 于 7 月 12 日星期五出售了公司股票的 17,475 股。股票的平均售价为 25.07 美元，总价值为 438,098.25 美元。交易完成后，首席运营官在公司拥有 376,552 股股票，价值约 9,440,158.64 美元。该交易已在提交给证券交易委员会（SEC）的文件中披露，可在 SEC 网站上查看。此外，首席运营官 Anish Patel 于 7 月 12 日星期五以 25.07 美元的平均价格出售了 17,475 股 Enliven Therapeutics 股票。交易完成后，首席运营官现在直接持有公司 376,552 股股票，价值 9,440,158.64 美元。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站查看。此外，内部人员 Joseph P. Lyssikatos 于 7 月 31 日星期三出售了 3,099 股 Enliven Therapeutics 股票。股票以 27.56 美元的平均价格出售，总价值为 85,408.44 美元。交易后，该内部人员现在持有公司 1,089,936 股股票，价值约 30,038,636.16 美元。上一季度内部人员出售了价值 3057633 美元的公司股票 123,668 股。公司股份的 29.20% 归内部人员所有。</p>
</div><h2>About Enliven Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Enliven Therapeutics（获取免费报告）</h2>
</div><p>Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.</p>
<div class="lb-trans"><p>Enliven Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于发现和开发小分子抑制剂，以帮助癌症患者。该公司的主要产品候选包括正在评估中的 ELVN-001，用于慢性髓细胞白血病成人的 I 期临床试验；以及用于具有 HER2 改变的实体肿瘤成人的 I 期临床试验的 ELVN-002。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Enliven Therapeutics</li>
<li>What is a SEC Filing?</li>
<li>Michael Burry's Alibaba Bet and the Broader Market Implications</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Jeff Brown's Exegesis AI Stock Picks</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock</li>
</ul>
<div class="lb-trans"><h2>精选文章</h2>
<ul>
<li>我们喜欢的五只股票比 Enliven Therapeutics 更好</li>
<li>什么是 SEC 备案？</li>
<li>迈克尔·伯里的阿里巴巴赌注及其对整个市场的影响</li>
<li>ETF 是否支付股息？你需要了解的</li>
<li>杰夫·布朗的 Exegesis AI 股票推荐</li>
<li>投资高市盈率成长股</li>
<li>沃伦·巴菲特的赌注：为什么伯克希尔哈撒韦买入了 Ulta 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RUxWTg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ELVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由 Narrative Science 技术和 MarketBeat 的财务数据生成，以向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Elon’s sprint to AI wealth (From InvestorPlace)(Ad)</p>
<div class="lb-trans"><p>→ 伊隆（Elon）追逐人工智能财富（来自 InvestorPlace）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTc3" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9177&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Enliven Therapeutics right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 Enliven Therapeutics？</h2>
</div><p>Before you consider Enliven Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Enliven Therapeutics 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 Enliven Therapeutics 不在名单上。</p>
</div><p>While Enliven Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Enliven Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Enliven Therapeutics（纳斯达克代码：ELVN）发布季度收益报告，每股收益超出预期 0.17 美元